A phase I study explored adoptive Natural Killer (NK) cell infusions for hepatocellular carcinoma (HCC) in patients with recurrent disease after liver transplantation. Investigators reported signals of tolerability and early anti‑tumor activity, positioning NK adoptive therapy as a potential salvage option for post‑transplant HCC recurrence. The trial, led by Yang, Gong and colleagues, focused on safety endpoints in a high‑risk population and suggested further evaluation in larger cohorts. Researchers emphasized challenges around post‑transplant immunosuppression and graft safety as priorities for next‑stage studies.